老年心绞痛患者血清Kalistatin、诱骗受体3与心功能和心血管不良事件的关系  

Relationship between Serum Concentrations of Kalistatin and Decoy Receptor 3 with Cardiac Function and Cardiovascular Adverse Events in Elderly Patients with Angina Pectoris

作　　者：陈静 陈喻[2] 彭雷 熊天中[1] CHEN Jing;CHEN Yu;PENG Lei;XIONG Tianzhong(Department of Cardiovascular Medicine,Zigong First People′s Hospital,Zigong,Sichuan 643000,China;Department of Laboratory,Zigong First People′s Hos-pital,Zigong,Sichuan 643000,China;Department of Information,Zigong First People′s Hospital,Zigong,Sichuan 643000,China)

机构地区：[1]自贡市第一人民医院心血管内科,四川自贡643000 [2]自贡市第一人民医院检验科,四川自贡643000 [3]自贡市第一人民医院信息科,四川自贡643000

出　　处：《岭南心血管病杂志》2025年第1期45-49,57,共6页South China Journal of Cardiovascular Diseases

基　　金：自贡市重点科技计划项目(项目编号:2017SF13)。

摘　　要：目的探讨老年不稳定型心绞痛(unstable angina pectoris,UAP)患者血清人激肽释放酶抑制剂(kallistatin)和诱骗受体3(decoy receptor 3,DcR3)与心功能和心血管不良事件(adverse cardiovascular events,ACE)的相关性。方法选取2021年9月至2023年2月期间自贡市第一人民医院收治的156例老年UAP患者作为UAP组,根据其治疗后1年内是否发生ACE分为ACE组(n=32)和无ACE组(n=124);另选取同期本院收治的87例稳定型心绞痛(stable angina pectoris,SAP)患者及76名体检健康者分别作为SAP组和对照组。采用酶联免疫吸附试验(enzyme-linked immunosorbent assay,ELISA)检测血清kallistatin和DcR3浓度;采用Pearson法分析老年UAP患者血清kal‐listatin和DcR3浓度与相关临床血清指标的相关性;采用受试者工作特征曲线(receiver operating characteristic curve,ROC)评估血清kallistatin和DcR3浓度对老年UAP患者发生ACE的预测价值。结果UAP组患者的血清kallistatin浓度明显低于SAP组和对照组,差异有统计学意义[(12.12±3.57)ng/mL vs.(21.46±5.39)ng/mL vs.(29.05±9.20)ng/mL,F=227.150,P<0.05]。UAP组患者的DcR3明显高于SAP组和对照组,差异有统计学意义[(19.68±4.75)ng/mL vs.(14.27±3.80)ng/mL vs.(4.24±1.21)ng/mL,F=397.232,P<0.05]。ACE和无ACE组患者左心室质量指数(left ventricular mass index,LVMI)、白细胞介素(interleukin,IL)-4、IL-10、IL-6和脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2,Lp-PLA2)浓度比较,差异有统计学意义(P<0.05)。UAP患者血清kallistatin与LVMI、IL-6和Lp-PLA2浓度均呈负相关(r=0.407、0.381、0.415,均P<0.05),DcR3与LVMI、IL-6和Lp-PLA2浓度均呈正相关(r=0.398、0.404、0.427,均P<0.05)。血清kallistatin和DcR3浓度单独及联合预测UAP患者发生ACE的曲线下面积(AUC)分别为0.792、0.868、0.928,联合优于单独预测(Z_(二者联合-kallistatin)=2.688、P=0.007,Z_(二者联合-DcR3)=2.050,P=0.040)。结论UAP患者血清kallistatin浓度明显降低,DcR3浓度明显升�Objectives To explore the correlation between serum concentrations of kalistatin and decoy receptor 3(DcR3)with cardiac function and adverse cardiovascular events(ACE)in elderly patients with unstable angina pectoris(UAP).Methods A total of 156 elderly UAP patients admitted to Zigong First People′s Hospital between September 2021 and February 2023 were regarded as UAP group.They were separated into ACE group(n=32)and non ACE group(n=124)based on whether they experienced ACE within one year after treatment.Additionally,87 patients with stable angina pectoris(SAP)and 76 healthy individuals undergoing physical examination admitted to Zigong First People′s Hospital were regarded as SAP group and control group,respectively.Enzyme linked immunosorbent assay(ELISA)was applied to detect serum concentrations of kallistatin and DcR3.Pearson method was applied to analyze the correlation between serum concentrations of kallistatin and DcR3 with relevant clinical serum indicators in elderly UAP patients.Receiver operating characteristic curve(ROC)was applied to evaluate the predictive value of serum concentrations of kallistatin and DcR3 for the occurrence of ACE in elderly UAP patients.Results The serum concentration of kalistatin in UAP group was greatly lower than that in SAP group and control group[(12.12±3.57)ng/mL vs.(21.46±5.39)ng/mL vs.(29.05±9.20)ng/mL,F=227.150,P<0.05].The serum concentration of DcR3 in UAP group was greatly higher than that in SAP group and control group[(19.68±4.75)ng/mL vs.(14.27±3.80)ng/mL vs.(4.24±1.21)ng/mL,F=397.232,P<0.05].The differences in left ventricular mass index(LVMI),concentrations of interleukin(IL)-4,IL-10,IL-6,and lipoprotein associated phospholipase A2(Lp PLA2)between ACE and non ACE groups were statistically great(P<0.05).The serum concentration of kalistatin in UAP patients was negatively correlated with LVMI and concentrations of IL-6,Lp PLA2(r=0.407,0.381,0.415,all P<0.05),while serum concentration of DcR3 was positively correlated with LVMI and concen⁃trations of

关 键 词：心绞痛 人激肽释放酶抑制剂 诱骗受体3 心功能 心血管不良事件 

分 类 号：R542[医药卫生—心血管疾病]